Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 372 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control - Inhibition Clear all
Completed Not applicable Interventional

Central Executive Training (CET) for ADHD

NCT03324464
View directory record Official record
Conditions
ADHD
Interventions
Central Executive Training: Working Memory, Central Executive Training: Inhibitory Control
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
8 Years to 12 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) in Pediatric Obsessive Compulsive Disorder (OCD)

NCT04548609
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Pediatric Psychiatric Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of SLV213 for the Treatment of COVID-19.

NCT06146374
View directory record Official record
Conditions
COVID-19
Interventions
Placebo for SLV213, SLV213
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated No phase listed Observational

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609
View directory record Official record
Conditions
Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Cirrhosis
Interventions
Oral glutamine challenge, Psychometric Tests
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 21, 2026, 8:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers

NCT01314378
View directory record Official record
Conditions
Tobacco Smoking, Nicotine Dependence, Impulsivity, Addiction, Substance Dependence
Interventions
Mindfulness Training, Cognitive-Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Olatorepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Mobile, Alabama • Walnut Creek, California • Waterbury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04773587
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Montgomery, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BID WM Digital Intervention in Aging

NCT06918704
View directory record Official record
Conditions
Working Memory, Inhibitory Control, Mild Cognitive Impairment (MCI), Aging
Interventions
Coherence, Worder
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Self-Control in Bulimia Nervosa

NCT04409457
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
fasting state, fed state, magnetic resonance imaging
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

LPFC Organization in Emotion-Duration Difference Estimation

NCT06276400
View directory record Official record
Conditions
Healthy
Interventions
Emotion valence, Time, TMS Stimulation
Other · Device
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Executive Function/Metacognitive Training for At-Risk Preschoolers

NCT01675869
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Executive Training of Attention and Metacognition (ETAM), Attention Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Transcranial Stimulation for Essential Tremor

NCT03025529
View directory record Official record
Conditions
Essential Tremor
Interventions
Transcranial Magnetic Stimulation, Sham Transcranial Magnetic Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
tocilizumab, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

NCT07435129
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD
Interventions
Apitegromab, Placebo
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

NCT02561000
View directory record Official record
Conditions
Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions
PZ-128, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167
View directory record Official record
Conditions
Heart Diseases, Postoperative Complications
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
27,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
326
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Not applicable Interventional

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

NCT05198232
View directory record Official record
Conditions
Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions
Zumba High Tempo, Zumba Low Tempo
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 21, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD

NCT07219810
View directory record Official record
Conditions
ADHD
Interventions
intermittent theta burst stimulation (iTBS)
Device
Lead sponsor
Bradley Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 21, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176
View directory record Official record
Conditions
Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 21, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

NCT01763918
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 21, 2026, 8:14 PM EDT